Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments

Clarke, William T; Feuerstein, Joseph D.

doi:10.3748/wjg.v25.i30.4148

Cited by 131 publications

(83 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous studies have shown that inflammatory bowel diseases (IBDs), including Crohn’s disease and ulcerative colitis (UC), are associated with the development and progression of CRC [ 4 , 5 , 6 ]. It has been reported that 25% of patients with IBD have colon cancer [ 7 , 8 ]. Based on the evidence of a strong association between IBD and CRC, colitis-associated cancer (CAC) has been proposed and is currently recognized as a special subtype of CRC.…”

Section: Introductionmentioning

confidence: 99%

Fusobacterium nucleatum Accelerates the Progression of Colitis-Associated Colorectal Cancer by Promoting EMT

Kim

Park

2020

Cancers

View full text Add to dashboard Cite

Recently, it has been reported that Fusobacterium nucleatum, a major pathogen involved in chronic periodontitis, may play an important role in colorectal cancer (CRC) progression. In addition, inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease represent major predisposing conditions for the development of CRC, and this subtype of cancer is called colitis-associated cancer (CAC). Although the importance of F. nucleatum in CRC has attracted attention, its exact role and related mechanism in CAC progression remain unclear. In this study, we investigated the effects of F. nucleatum in experimental colitis induced with dextran sodium sulfate (DSS), which is a well-known colitis-inducing chemical, on the aggressiveness of CAC and its related mechanism in both in vitro and in vivo models. F. nucleatum synergistically increased the aggressiveness and epithelial–mesenchymal transition (EMT) characteristics of CRC cells that were treated with DSS compared to those in non-treated CRC cells. The role of F. nucleatum in CAC progression was further confirmed in mouse models, as F. nucleatum was found to significantly increase the malignancy of azoxymethane (AOM)/DSS-induced colon cancer. This promoting effect of F. nucleatum was based on activation of the EGFR signaling pathways, including protein kinase B (AKT) and extracellular signal-regulated kinase (ERK), and epidermal growth factor receptor (EGFR) inhibition significantly reduced the F. nucleatum-induced EMT alteration. In conclusion, F. nucleatum accelerates the progression of CAC by promoting EMT through the EGFR signaling pathway.

show abstract

Section: Introductionmentioning

confidence: 99%

Fusobacterium nucleatum Accelerates the Progression of Colitis-Associated Colorectal Cancer by Promoting EMT

Kim

Park

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…First-degree relatives of CRC patients have a threefold greater risk of developing CRC than individuals without familial predisposition. Patients with inflammatory bowel diseases are also at an increased risk of CRC [39]. The prognosis of CRC depends largely on the cancer stage at the time of diagnosis.…”

Section: Colorectal Cancer: An Overviewmentioning

confidence: 99%

Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy

Turano

Delrio

Rega

et al. 2019

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) has been ranked as the third most prevalent cancer worldwide. Indeed, it represents 10.2% of all cancer cases. It is also the second most common cause of cancer mortality, and accounted for about 9.2% of all cancer deaths in 2018. Early detection together with a correct diagnosis and staging remains the most effective clinical strategy in terms of disease recovery. Thanks to advances in diagnostic techniques, and improvements of surgical adjuvant and palliative therapies, the mortality rate of CRC has decreased by more than 20% in the last decade. Cancer biomarkers for the early detection of CRC, its management, treatment and follow-up have contributed to the decrease in CRC mortality. Herein, we provide an overview of molecular biomarkers from tumor tissues and liquid biopsies that are approved for use in the CRC clinical setting for early detection, follow-up, and precision therapy, and of biomarkers that have not yet been officially validated and are, nowadays, under investigation.

show abstract

“…In addition, inflammatory bowel disease (IBD) and chronic colitis have also been associated with an increased risk of CRC development (10,11). However, improved anti-inflammatory treatments and increased surveillance have been effective in reducing CRC incidence for these patients (12).…”

Section: Introduction Colorectal Cancer-epidemiology Pathophysiologymentioning

confidence: 99%

Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword

et al. 2020

View full text Add to dashboard Cite

The immune system plays a fundamental role at mucosal barriers in maintaining tissue homeostasis. This is particularly true for the gut where cells are flooded with microbial-derived signals and antigens, which constantly challenge the integrity of the intestinal barrier. Multiple immune cell populations equipped with both pro-and anti-inflammatory functions reside in the gut tissue and these cells tightly regulate intestinal health and functions. Dysregulation of this finely tuned system can progressively lead to autoimmune disease and inflammation-driven carcinogenesis. Over the last decade, the contribution of the adaptive immune system in controlling colorectal cancer has been studied in detail, but the role of the innate system, particularly innate lymphoid cells (ILCs), have been largely overlooked. By sensing their microenvironment, ILCs are essential in supporting gut epithelium repair and controling bacterial-and helminth-mediated intestinal infections, highlighting their important role in maintaining tissue integrity. Accumulating evidence also suggests that they may play an important role in carcinogenesis including intestinal cancers. In this review, we will explore the current knowledge about the pro-and anti-tumor functions of ILCs in colorectal cancer.

show abstract

Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments

Cited by 131 publications

References 74 publications

Fusobacterium nucleatum Accelerates the Progression of Colitis-Associated Colorectal Cancer by Promoting EMT

Fusobacterium nucleatum Accelerates the Progression of Colitis-Associated Colorectal Cancer by Promoting EMT

Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy

Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword

Contact Info

Product

Resources

About